1. Qin Y, Huang X, Chen H, et al. Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):551.
2. Sethuraman N, Thirunarayan MA, Gopalakrishnan R, Rudramurthy S, Ramasubramanian V, Parameswaran A. Talaromyces marneffei outside endemic areas in India: an emerging infection with atypical clinical presentations and review of published reports from India. Mycopathologia. 2020;185(5):893–904.
3. Mohsin J, Khalili SA, van den Ende A, et al. Imported talaromycosis in Oman in advanced HIV: a diagnostic challenge outside the endemic areas. Mycopathologia. 2017;182(7–8):739–45.
4. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America: 2021 update. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 12 Nov 2021.
5. Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med. 2017;376(24):2329–40.